Currently, Alx Oncology Holdings Inc [ALXO] is trading at $12.23, up 8.81%. An important factor to consider is whether the stock is rising or falling in short-term value. The ALXO shares have gain 9.69% over the last week, with a monthly amount drifted -17.20%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, March 2024, ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
From an analyst’s perspective:
Alx Oncology Holdings Inc [NASDAQ: ALXO] stock has seen the most recent analyst activity on March 08, 2024, when Stifel downgraded its rating to a Hold and also boosted its price target to $14 from $10. Previously, Jefferies upgraded its rating to Buy on December 08, 2023, and elevated its price target to $18. On December 22, 2021, downgrade downgraded it’s rating to Hold and revised its price target to $25 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $106 on September 30, 2021. In a note dated April 06, 2021, UBS initiated an Buy rating.
This stock has fluctuated between a low of $3.94 and a high of $17.42 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Alx Oncology Holdings Inc [NASDAQ: ALXO] shares were valued at $12.23 at the most recent close of the market. An investor can expect a potential return of 120.77% based on the average ALXO price forecast.
Analyzing the ALXO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -3.15 and Total Capital is -0.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.38 points at the first support level, and at 10.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.69, and for the 2nd resistance point, it is at 13.15.
Alx Oncology Holdings Inc [ALXO] reported earnings per share of -$0.93 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.84/share, meaning a difference of -$0.09 and a surprise factor of -10.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.24 per share as compared to estimates of -$0.87 per share, a difference of -$0.37 representing a surprise of -42.50%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Alx Oncology Holdings Inc [NASDAQ:ALXO] is 5.24. On the other hand, the Quick Ratio is 5.24, and the Cash Ratio is 0.62.
Transactions by insiders
Recent insider trading involved Pons Jaume, PRESIDENT & CSO, that happened on Apr 04 ’24 when 20000.0 shares were sold. CHIEF EXECUTIVE OFFICER, Lettmann Jason completed a deal on Mar 14 ’24 to buy 4400.0 shares. Meanwhile, SVP, Finance and CAO Pinto Shelly sold 2717.0 shares on Jan 04 ’24.
